Germany Erlangen3 August 2023 /PRNewswire/ -- Siemens Healthcare recently released its quarterly report for the third quarter of FY2023 from April 1, 2023 to June 30, 2023.

Third quarter of fiscal year 2023

• Total equipment orders clearly exceeded the strong growth of total equipment revenue; equipment order shipment ratio reached 1.11
• Excluding the rapid COVID-19 antigen testing business, comparable revenue increased by 10.1%; taking into account this shrinking demand business, comparable revenue increased by 3.6%
• The comparable revenue of the video business increased by 15.2%, and the adjusted profit margin before interest and tax increased by 21.8% over the same period last year
• Due to the decline in the rapid COVID-19 antigen testing business volume, the comparative revenue of the laboratory diagnosis business decreased by 20.1%; excluding the rapid COVID-19 antigen testing business, comparable revenue increased by 2%; adjusted profit margin before interest and tax decreased 0.5% year-on-year; excluding rapid COVID-19 antigen testing business and transformation project costs, the adjusted profit margin before interest and tax increased 1.0% year-on-year
• Comparable revenue from Varian's business increased 6.7%, and the adjusted profit margin before interest and taxes was 12.1%
• The comparable revenue of the clinical treatment business increased by 11.9%, and the adjusted profit margin before interest and tax reached 15.3%, significantly higher than the same period last year
• Mainly affected by the decline in rapid COVID-19 antigen testing business volume, the overall adjusted profit margin before interest and tax fell slightly to 14.2%
• Adjusted basic earnings per share were €0.53

FY2023 outlook

Siemens HealthcareConfirmed, comparable revenue for FY2023 is expected to grow by -1% to 1%. In addition to the rapid testing business for COVID-19 antigen, other types of businesses are expected to increase comparable revenue by 6% to 8%. The adjusted basic earnings per share are expected to reach €2.00 to €2.20.

Bernd Montag (Bernd Montag), CEO of Siemens Healthcare: “We continued to make great strides in the third quarter, which shows that our various innovations have created unique value and meaning for customers and patients around the world.”

About Siemens Healthcare

Siemens Healthcare (Frankfurt Stock Exchange: SHL), based in Erlangen, Germany, is a leading medical technology company committed to continuously developing a portfolio of products and services, including AI-based applications and digital products that play an increasingly important role in the development of next-generation medical technology. These new applications will further strengthen the company's foundation in the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis, and novel cancer diagnosis and treatment. At the same time, Siemens Healthcare provides a wide range of services and solutions to help medical service providers improve their capabilities and provide high-quality and efficient services to patients. In fiscal year 2022 (ending September 30, 2022), Siemens Healthcare's total revenue was €21.7 billion and has approximately 69,500 employees worldwide.

The realm of innovation, for every life! For more information, visit Siemens Healthcare's official website: